US health agencies have stopped the use of the Corona vaccine created by pharma company Johnson & Johnson Company with immediate effect. Earlier, there were problems in the health of 6 people taking vaccines in America. Some people complained of blood clots within 2 weeks of vaccination. US agencies have temporarily imposed this prohibition, and now the US FDA will investigate cases of discrepancies.
The 6 Americans who took Johnson & Johnson’s Corona vaccine were between the ages of 18 and 48. One of these women died and the other woman is admitted in hospital in critical condition.
This vaccine has been installed by 7 million people in America
So far, about seven million people in the United States have had Johnson & Johnson’s Corona vaccine shot. Apart from this, about 90 lakh doses have been sent to the states.
The USFDA has issued a statement saying that ‘We are currently putting a temporary moratorium on Johnson & Johnson’s Corona vaccine. The administration is investigating the cases of disorder in America.
Two vaccines are being introduced in India now.
Let us know that there are two types of Corona vaccine in India. AstraZeneca with one indigenous covaxine and the other Oxford. This second one is AstraZeneca, which is currently banned by many countries in Europe.
About a dozen countries including Italy, France, Denmark, Ireland, Netherlands, Norway and Germany. There are complaints that blood clots are freezing. So in some cases there is a complaint of excessive bleeding. There are deaths
AstraZeneca vaccine also complains of blood clots
A few days ago, a European Drug Regulatory (EMA) study revealed that blood clots may accumulate after the introduction of the AstraZeneca vaccine. According to the European drug regulator, a relationship has been found between the AstraZeneca vaccine and blood clots. However, this is quite rare, but it can still happen. It has been advised that this thing should be taken care of. Also, it has also been said that the vaccine has more advantages than having the Corona vaccine as compared to the risk.